SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy.

Citation data:

Scientific reports, ISSN: 2045-2322, Vol: 6, Issue: 1, Page: 35732

Publication Year:
2016
Usage 4
Abstract Views 4
Captures 29
Readers 28
Exports-Saves 1
Social Media 1
Tweets 1
Citations 12
Citation Indexes 12
Repository URL:
http://scholarworks.unist.ac.kr/handle/201301/20666
PMID:
27767079
DOI:
10.1038/srep35732
PMCID:
PMC5073315
Author(s):
Kim, Kwang-Youn Kim; Jang, Hyun-Jun; Yang, Yong Ryul; Park, Kwang-Il; Seo, Jeong Kon; Shin, Il-Woo; Jeon, Tae-Il; Ahn, Soon-cheol; Suh, Pann-Ghill; Osborne, Timothy F.; Seo, Young Kyo Show More Hide
Publisher(s):
Springer Nature; NATURE PUBLISHING GROUP
Tags:
Multidisciplinary; Pre-diabetes; Transcriptional regulatory elements
Most Recent Tweet View All Tweets
article description
Dysregulated autophagy is associated with steatosis and non-alcoholic fatty liver disease (NAFLD), however the mechanisms connecting them remain poorly understand. Here, we show that co-administration of lovastatin and ezetimibe (L/E) significantly reverses hepatic triglyceride accumulation concomitant with an increase in SREBP-2 driven autophagy in mice fed a high-fat diet (HFD). We further show that the statin mediated increase in SREBP-2 directly activates expression of patatin-like phospholipase domain-containing enzyme 8 (PNPLA8) gene, and PNPLA8 associates with autophagosomes and is associated with a decrease in cellular triglyceride. Moreover, we show that over-expression of PNPLA8 dramatically decreases hepatic steatosis through increased autophagy in hepatocytes of HFD-fed mice. Live-cell imaging analyses also reveal that PNPLA8 dynamically interacts with LC3 and we suggest that the SREBP-2/PNPLA8 axis represents a novel regulatory mechanism for lipid homeostasis. These data provide a possible mechanism for the reported beneficial effects of statins for decreasing hepatic triglyceride levels in NAFLD patients.